MLYS logo

Mineralys Therapeutics Inc. (MLYS)

$14.48

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on MLYS

Market cap

$1.28B

EPS

-4.28

P/E ratio

--

Price to sales

--

Dividend yield

--

Beta

0.825685

Price on MLYS

Previous close

$14.53

Today's open

$14.63

Day's range

$14.30 - $14.80

52 week range

$14.30 - $45.62

Profile about MLYS

CEO

Jon Congleton

Employees

76

Headquarters

Radnor, PA

Exchange

Nasdaq Global Select

Shares outstanding

88557097

Issue type

Common Stock

MLYS industries and sectors

Healthcare

Biotechnology & Life Sciences

News on MLYS

Mineralys Therapeutics Presents New Late-Breaking Data from Transform-HTN Open-Label Extension Trial of Lorundrostat in Hypertension at AHA Scientific Sessions 2026

– In the largest long-term hypertension trial of an aldosterone synthase inhibitor to date, lorundrostat demonstrated sustained reduction in automated office systolic blood pressure (AOSBP) of 17.8 mmHg at Week 48 from Launch-HTN baseline –

news source

GlobeNewsWire • Nov 8, 2026

news preview

Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

RADNOR, Pa., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced today that, on November 3, 2026, the Compensation Committee of Mineralys' Board of Directors granted an inducement stock option award covering 14,880 shares and an inducement restricted stock unit award covering 11,160 shares of Mineralys common stock to a new non-executive employee.

news source

GlobeNewsWire • Nov 6, 2026

news preview

Mineralys: Fairly Valued Near $17 As Baxfendy Launch Validates Slow ASI Ramp (Upgrade)

Mineralys Therapeutics is launching lorundrostat, a second-to-market ASI, with limited differentiation from BAXFENDY on efficacy or safety. MLYS faces AstraZeneca's entrenched cardiorenal franchise, restrictive payer policies, and step therapy barriers, limiting near-term market penetration. Peak sales for lorundrostat are modeled at ~$800 million, but the current valuation appears fair; I upgrade from 'Sell' to 'Hold' given the risk/reward balance.

news source

Seeking Alpha • Nov 5, 2026

news preview

What Mineralys Therapeutics (MLYS) Said on Its Q3 Earnings Call

Mineralys Therapeutics NASDAQ: MLYS is preparing to launch its hypertension drug candidate lorundrostat if it wins regulatory approval, with a U.S. Food and Drug Administration decision targeted for Dec. 22, executives said on the company's third-quarter earnings call.

news source

MarketBeat • Nov 5, 2026

news preview

Mineralys Therapeutics, Inc. (MLYS) Q3 2026 Earnings Call Transcript

Mineralys Therapeutics, Inc. (MLYS) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 5, 2026

news preview

Mineralys Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

– Commercialization plans for lorundrostat are on track ahead of PDUFA target date of December 22, 2026 – – New analyses from the pivotal Launch-HTN trial showed 46% of participants with uncontrolled or resistant hypertension receiving lorundrostat 50 mg achieved the AHA/ACC guideline systolic blood pressure target of

news source

GlobeNewsWire • Nov 4, 2026

news preview

Mineralys Therapeutics to Participate in Upcoming Investor Conferences

RADNOR, Pa., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, today announced that members of senior management will be participating in fireside chats at three upcoming investor conferences.

news source

GlobeNewsWire • Nov 3, 2026

news preview

Mineralys Therapeutics to Announce Third Quarter 2026 Financial Results and Host Conference Call on Wednesday, November 4, 2026

RADNOR, Pa., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced it will report its financial results from the third quarter ended September 30, 2026, after the financial markets close on Wednesday, November 4, 2026.

news source

GlobeNewsWire • Oct 28, 2026

news preview

Mineralys Therapeutics Announces Publication of Phase 2 Explore-CKD Trial Results for Lorundrostat in Kidney International

- Explore-CKD met its primary endpoint; lorundrostat 25 mg once daily added to an SGLT2 inhibitor achieved a statistically significant reduction in systolic blood pressure at four weeks -

news source

GlobeNewsWire • Oct 28, 2026

news preview

Mineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026

In the large, pivotal Phase 3 Launch-HTN trial, lorundrostat achieved similar significant blood pressure reductions in participants with and without CKD, with consistent reductions across Stages 1-3 CKD

news source

GlobeNewsWire • Oct 22, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Mineralys Therapeutics Inc.

Open an M1 investment account to buy and sell Mineralys Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in MLYS on M1